Personalized therapy in pain management: where do we stand?

Area of Science:

• Pharmacogenetics
• Pain Management
• Genomic Medicine

Background:

• Genetic variations significantly influence individual responses to pain pharmacotherapy.
• Drug-metabolizing enzymes, particularly cytochrome P450 (CYP) enzymes, are key targets for understanding these genetic influences.
• Polymorphisms in CYP2D6 affect the metabolism of opioids and antidepressants, while CYP2C9 and CYP2C8 influence NSAID blood concentrations and side effect profiles.

Purpose of the Study:

• To investigate genomic variations that affect patient response to pain pharmacotherapy.
• To identify associations between genetic profiles and drug response, focusing on drug-metabolizing enzymes.
• To review current understanding and challenges in applying pharmacogenetics to pain management.

Main Methods:

• Review of existing literature on pharmacogenetics in pain management.
• Analysis of the role of cytochrome P450 enzyme polymorphisms (e.g., CYP2D6, CYP2C9, CYP2C8).
• Discussion of other candidate genes, including opioid receptors and transporters.

Main Results:

• CYP2D6 polymorphisms impact the metabolism of codeine, tramadol, hydrocodone, oxycodone, and tricyclic antidepressants.
• Genomic variants in CYP2C9 and CYP2C8 correlate with NSAID blood concentrations and side effect profiles.
• Results for other candidate genes are often equivocal, highlighting the complexity of pain pharmacogenetics.

Conclusions:

• Pharmacogenetics holds potential for improving patient-specific pain therapy.
• Factors beyond genetics, such as age, disease, and medication compliance, also critically influence treatment outcomes.
• Well-designed studies are essential to validate the superiority of pharmacogenetic-guided dosing over conventional methods.